- Home
- DNTH vs CVAC Comparison
DNTH vs CVAC Comparison
Compare DNTH & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- CVAC
- Stock Information
- Founded
- DNTH 2015
- CVAC 2000
- Country
- DNTH United States
- CVAC Germany
- Employees
- DNTH N/A
- CVAC N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- CVAC Health Care
- Exchange
- DNTH Nasdaq
- CVAC Nasdaq
- Market Cap
- DNTH 1.4B
- CVAC 1.2B
- IPO Year
- DNTH N/A
- CVAC 2020
- Fundamental
- Price
- DNTH $33.73
- CVAC $5.27
- Analyst Decision
- DNTH Strong Buy
- CVAC Hold
- Analyst Count
- DNTH 11
- CVAC 3
- Target Price
- DNTH $65.22
- CVAC $6.83
- AVG Volume (30 Days)
- DNTH 503.3K
- CVAC 520.0K
- Earning Date
- DNTH 11-05-2025
- CVAC 11-12-2025
- Dividend Yield
- DNTH N/A
- CVAC N/A
- EPS Growth
- DNTH N/A
- CVAC N/A
- EPS
- DNTH N/A
- CVAC 1.01
- Revenue
- DNTH $4,854,000.00
- CVAC $599,540,810.00
- Revenue This Year
- DNTH N/A
- CVAC N/A
- Revenue Next Year
- DNTH N/A
- CVAC $23.40
- P/E Ratio
- DNTH N/A
- CVAC $5.24
- Revenue Growth
- DNTH 17.87
- CVAC 675.15
- 52 Week Low
- DNTH $13.37
- CVAC $2.37
- 52 Week High
- DNTH $40.16
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- DNTH 47.36
- CVAC 30.97
- Support Level
- DNTH $32.28
- CVAC $5.33
- Resistance Level
- DNTH $35.40
- CVAC $5.41
- Average True Range (ATR)
- DNTH 1.62
- CVAC 0.03
- MACD
- DNTH -0.20
- CVAC -0.01
- Stochastic Oscillator
- DNTH 27.78
- CVAC 0.00
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.